Image_7_Anti-inflammatory Therapies for Coronary Heart Disease: A Systematic Review and Meta-Analysis.TIF
Background: Anti-inflammatory therapy has been proposed as a promising treatment for coronary heart disease (CHD) that could reduce residual inflammation risk (RIR) and therefore major adverse cardiovascular events. We implemented a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the clinical benefits of anti-inflammatory agents in patients with CHD based on secondary cardiovascular prevention.
Methods: We systemically searched the PubMed, Embase, and Cochrane Library databases for RCTs (published between Jan 1, 1950, and June 1, 2021; no language restrictions) that focused on anti-inflammatory therapy for coronary heart disease. Our primary end points of interest were a composite of all-cause death, recurrent myocardial infarction and stroke. We processed pooled data using a random-effects model.
Results: Of 1497 selected studies, 18 studies with 67,449 participants met our inclusion criteria and were included in the present meta-analysis. Comparing anti-inflammatory agents with placebo, there was no significant decrease in risk of primary end points, secondary end points, all-cause mortality, cardiac mortality, recurrent myocardial infarction, stroke or revascularization. Further subgroup analysis indicated that anti-inflammatory agents led to a significant reduction in secondary end points (OR 0.87, CI 0.77–0.99; P = 0.03), recurrent myocardial infarction (OR 0.86, CI 0.78–0.95; P = 0.003) and revascularization (OR 0.81, CI 0.70–0.92; P = 0.001) in patients with stable CHD compared with placebo. Moreover, stable CHD patients had a lower propensity for recurrent myocardial infarction than acute coronary syndrome (ACS) patients when using anti-inflammatory agents (P = 0.03). The colchicine subgroup analysis showed that colchicine yielded a promising reduction in the primary end points (OR 0.81, CI 0.70–0.95; P = 0.009) compared with placebo. Anti-inflammatory agents were associated with a higher risk of infection (OR 1.13, CI 1.03–1.23; P = 0.007) and negligible effects on cancers (OR 0.98, CI 0.90–1.06; P = 0.61).
Conclusion: Anti-inflammatory agents appear to have beneficial effects in reducing the risk of recurrent myocardial infarction in patients with stable CHD, albeit at the cost of increased infection. Notably, colchicine demonstrates a promising cardioprotective effect with a lower incidence of major cardiovascular events and thus is a potential therapeutic strategy for stable CHD patients.
Systematic Review Registration: PROSPERO, identifier CRD42021245514.
History
References
- https://doi.org//10.1016/j.cjca.2020.10.006
- https://doi.org//10.1155/2020/4904217
- https://doi.org//10.1161/CIRCULATIONAHA.114.008720
- https://doi.org//10.1038/nri3800
- https://doi.org//10.1155/2021/5160728
- https://doi.org//10.1016/j.atherosclerosis.2018.07.007
- https://doi.org//10.1056/NEJMoa1707914
- https://doi.org//10.1161/CIRCULATIONAHA.119.045256
- https://doi.org//10.1056/NEJMoa2021372
- https://doi.org//10.1016/j.jacbts.2017.07.001
- https://doi.org//10.7326/0003-4819-151-4-200908180-00135
- https://doi.org//10.1056/NEJMoa1315878
- https://doi.org//10.1056/NEJMoa1809798
- https://doi.org//10.1016/j.jacc.2012.10.027
- https://doi.org//10.1161/CIRCULATIONAHA.120.050771
- https://doi.org//10.1001/jama.2014.11061
- https://doi.org//10.1001/jama.2016.3609
- https://doi.org//10.1161/CIRCINTERVENTIONS.119.008717
- https://doi.org//10.1016/j.jacc.2013.03.003
- https://doi.org//10.1016/j.jacc.2010.06.015
- https://doi.org//10.1161/JAHA.119.014941
- https://doi.org//10.1001/jama.297.1.43
- https://doi.org//10.1161/01.CIR.0000087447.12918.85
- https://doi.org//10.1093/eurheartj/ehu272
- https://doi.org//10.1001/jama.2013.282836
- https://doi.org//10.1056/NEJMoa1912388
- https://doi.org//10.1016/j.amjcard.2014.11.003
- https://doi.org//10.1161/CIRCRESAHA.118.313129
- https://doi.org//10.1093/eurheartj/ehaa099
- https://doi.org//10.1161/CIR.0000000000000699
- https://doi.org//10.1161/CIRCULATIONAHA.118.034864
- https://doi.org//10.1002/14651858.CD011047.pub2
- https://doi.org//10.1161/CIRCRESAHA.114.302699
- https://doi.org//10.1038/nrcardio.2014.28
- https://doi.org//10.1016/S0735-1097%2810%2980161-5
- https://doi.org//10.1161/CIRCULATIONAHA.117.029870
- https://doi.org//10.1002/cbin.10988
- https://doi.org//10.3389/fcvm.2020.631398
- https://doi.org//10.1016/0016-5085%2895%2990696-7
- https://doi.org//10.1016/j.toxrep.2021.07.009